MNKD News & Analysis

MannKind Corporation (MNKD) Price Target Raised to $11 by Wells Fargo

On June 1, Wells Fargo increased its price target for MannKind Corporation (MNKD) from $10 to $11, maintaining an Overweight rating. This adjustment is attributed to the recent FDA approval of Afrezza Inhalation Powder for pediatric patients aged 6 and older. MannKind also indicated the possibility of receiving up to $35 million in development milestones along with a 10% royalty on net sales. These developments enhance MNKD's potential in the biopharmaceutical market, particularly in treating diabetes in children and adolescents.